#ACR22 Abs 1752 finds rates of incident cancer did not differ between patients treated with anti-TNF and other bDMARDs or tsDMARDs. @RheumNow https://t.co/ycnQzrmAjw https://t.co/CSgDq2Gazg
Links:
Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic a…
http://ow.ly/H2vu50LA4Rk
14-11-2022